|By Marketwired .||
|July 8, 2014 09:17 AM EDT||
SAN DIEGO, CA -- (Marketwired) -- 07/08/14 -- SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it is expanding the MORDIS evaluation of the colon application of the WavSTAT4 Optical Biopsy System at St. James NHS University Hospital in Leeds, England.
The WavStat trial in the UK is conducted in collaboration with the Colorectal Therapies Healthcare Technology Co-operative (HTC) based at St. James University Hospital, Leeds. Dr. Venkat Subramanian will be the principal investigator for the MORDIS trial in the UK.
The NHS was recently voted as the world's best healthcare system based on quality access and efficiency. The National Institute for Health Research (NIHR) serves as the liaison between industry and the clinicians of the National Health Service (NHS) and facilitates clinical evaluations of new products and technologies of interest to the NHS.
Providing NHS clinical validation of WavSTAT4 will enable SpectraScience to enter into the National Institute for Health and Clinical Excellence (NICE) MedTech evaluation program this fall.
NICE offers guidance on use of Medical technology across the NHS, said Michael Oliver, SpectraScience's President and CEO. "With the successful implementation of the clinical evaluation in UK, we can quickly establish both the clinical and economic value for the NHS. Our system is faster for clinicians, safer for patients and less expensive than pathology for the health system."
Mr. Oliver added, "Our WavSTAT4 Optical Biopsy System provides a fast, safe, accurate and cost-effective way to differentiate benign and cancerous lesions in the colon with a 96% negative predictive value. We look forward to working with Dr. Subramanian, St. James University Hospital and to eventually make the WavSTAT4 optical biopsy system available for colorectal cancer screening throughout the NHS."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
Media and Investors:
Phone: (858) 847-0200 x2019
Email: Email Contact